arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Coherus Oncology, Inc.

CHRS
$1.26 ▼ -0.04 (-3.08%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
55 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
39
Health
Weak
Neutral
auto_awesome

Analytical Summary

Coherus Oncology, Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $195.1M
Dividend Yield
Revenue Growth 39.5%
Op. Margin -226.0%
ROIC -42.0%
FCF / Share $-0.40
Trailing P/E
Price / Book 3.2x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

55-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$14.31M
↑ +39.5%
Net Income Profit after all expenses
$-38.33M
↑ +32.2%
Operating Margin Operating profit as % of sales
-226.0%
↑ +23.1% 0th
FCF / Share Free cash flow per share
$-0.40
↑ +5.5%
Long-Term Debt Long-term obligations
$73.29M
— +0.2%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile

Health Breakdown

Profitability
0
Returns
100
Financial Health
24
Cash Quality
11

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 15 years · 55 quarters